pioglitazone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 296 Diseases   92 Trials   92 Trials   3449 News 


«12...910111213141516171819...4849»
  • ||||||||||  pioglitazone / Generic mfg.
    Review, Journal:  SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. (Pubmed Central) -  Apr 19, 2022   
    Among the most studied is pioglitazone, either alone or in combination with vitamin E, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors...Experimental studies in animal models have suggested that SGLT2 inhibitors may have beneficial modulatory effects on NAFLD/NASH, and several trials in patients have proven their beneficial effects on liver enzymes, BMI, blood lipids, blood glucose, and insulin resistance in NAFLD patients, thus creating strong expectations for their possible use in preventing the evolution of liver damage in these patients. We will review the main pathogenetic mechanisms, diagnostic modalities, and recent therapies of NAFLD, with particular attention to the use of SGLT2 inhibitors.
  • ||||||||||  Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Journal:  JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. (Pubmed Central) -  Apr 19, 2022   
    Some medications approved for the treatment of type 2 diabetes may reduce liver fat (SGLT2 inhibitors, insulin) or even reverse steatohepatitis in paired liver biopsy studies (GLP-1 RAs or pioglitazone) Overall the field of preventive metabolic medicine is expanding. Clinical lipidologists should become familiar with recent advances.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Chronic PPARγ Stimulation Shifts Amyloidosis to Higher Fibrillarity but Improves Cognition. (Pubmed Central) -  Apr 19, 2022   
    We undertook longitudinal β-amyloid positron emission tomography (Aβ-PET) imaging as a translational tool for monitoring of chronic treatment with the peroxisome proliferator-activated receptor gamma (PPARγ) agonist pioglitazone in Aβ model mice...These translational data suggest that a shift toward higher plaque fibrillarity protects cognitive function and brain integrity. Increases in the Aβ-PET signal upon immunomodulatory treatments targeting Aβ aggregation can thus be protective.
  • ||||||||||  Piqray (alpelisib) / Novartis
    Review, Journal:  Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. (Pubmed Central) -  Apr 13, 2022   
    Lifestyle modifications, mainly comprising a reduced-carbohydrate diet, and a designated stepwise, personalized antihyperglycemic regimen, based on metformin, sodium-glucose co-transporter 2 inhibitors, and pioglitazone, are the main tools required to address the insulin-resistant hyperglycemia induced by alpelisib. In this report, based on the consensus of 14 oncologists and seven endocrinologists, we provide guidance for hyperglycemia management strategies before, during, and after alpelisib therapy for HR+, HER2-, PIK3CA-mutated breast cancer, with a focus on a proactive, multidisciplinary approach.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Knowledge-Based Discovery of the Role and Mechanism of Resveratrol in Improving Glomerular Tether Cell Proliferation and Apoptosis in Diabetic Nephropathy. (Pubmed Central) -  Apr 12, 2022   
    A human model of diabetes mellitus was prepared by high sugar and high fat diet plus low dose streptozotocin (STZ, 35 mg/kg) and randomly grouped into four groups: the normal control group, the model group, the resveratrol group, and the pioglitazone group...Hepatic steatosis and damage were significantly reduced compared with the model group as observed by HE staining. Resveratrol has obvious effects on regulating glucolipid metabolism, and its mechanism of action is associated with its ability to increase the antioxidant activity of the body, activate the Akt signaling pathway, and improve liver pathological damage.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Pioglitazone-Loaded PLGA Nanoparticles: Towards the Most Reliable Synthesis Method. (Pubmed Central) -  Apr 9, 2022   
    In addition, a comparison of these synthetic methodologies in terms of nanoparticle size, polydispersity index (PDI), zeta potential (ζ), drug loading (DL%), entrapment efficiency (EE%), and stability is offered. According to the higher entrapment efficiency content, enhanced storage time and suitable particle size, the nanoprecipitation approach appears to be the simplest, most rapid and most reliable synthetic pathway for these drug nanocarriers, and we demonstrated a very slow drug release in PBS for the best formulation obtained by this synthesis.
  • ||||||||||  pioglitazone / Generic mfg.
    Preclinical, Journal:  Plukenetia conophora seed oil ameliorates streptozotocin-induced hyperglycemia and oxidative stress in rats. (Pubmed Central) -  Apr 7, 2022   
    Rats were assigned into non-diabetic control (NC) and diabetic control (DC; treated with vehicle), PCO (200 mg/kg) and pioglitazone (10 mg/kg)...PCO significantly reduced MDA level and attenuated STZ-induced depletion of GSH, catalase and SOD in the diabetic rats' plasma, liver and kidneys. These results suggest that consumption of Plukenetia conophora seed might offer protection against diabetes-induced hepatic and renal damage.
  • ||||||||||  pioglitazone / Generic mfg.
    Preclinical, Journal:  Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro. (Pubmed Central) -  Apr 6, 2022   
    Overall, it has been shown that the liver MPS model can be a useful tool to assess DILI and its association with changes in hepatic function. The model can additionally be used to assess how novel compounds behave in distinct patient subsets and how toxicity profiles may be affected by liver disease states (e.g., viral hepatitis, fatty liver disease).
  • ||||||||||  pioglitazone / Generic mfg.
    Preclinical, Journal:  Systemic Treatment with Pioglitazone Reverses Vision Loss in Preclinical Glaucoma Models. (Pubmed Central) -  Apr 5, 2022   
    Furthermore, treatment preserves and partially reverses vision loss in spite of continuously elevated intraocular pressure. These data suggest that pioglitazone may provide treatment benefits for those glaucoma patients experiencing continued vision loss.
  • ||||||||||  pioglitazone / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Journal:  Combined effects of pioglitazone and doxorubicin on migration and invasion of MDA-MB-231 breast cancer cells. (Pubmed Central) -  Apr 5, 2022   
    PPAR agonists - including GQ-11 - might be promising agents in a strategy to avoid tissue dysfunction and death after cardiothoracic surgeries. Co-administration of pioglitazone and doxorubicin might reduce cell migration in breast cancer tumor cells, and that cell migration function is independent of some specific proteins.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  NONALCOHOLIC FATTY LIVER DISEASE-RELATED RISK OF CARDIOVASCULAR DISEASE AND OTHER CARDIAC COMPLICATIONS. (Pubmed Central) -  Apr 1, 2022   
    The complex interplay between the liver and cardiometabolic risk factors contributes to CVD, arrhythmias and cardiac disease in NAFLD. There is an urgent need for a multidisciplinary approach to manage both liver disease and cardiometabolic risk, and to test the cardiovascular and cardiac effects of new drugs for NAFLD.
  • ||||||||||  lanifibranor (IVA337) / Inventiva
    Journal:  The metabolic triad of NAFLD, visceral adiposity and type 2 diabetes: implications for treatment. (Pubmed Central) -  Apr 1, 2022   
    (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown some beneficial effects on both NASH and liver fibrosis. Since NASH is a complex and multifactorial disease, it is conceivable that targeting different pathways, not only insulin resistance but also inflammation and fibrotic processes, is required to achieve NASH resolution.
  • ||||||||||  pioglitazone / Generic mfg.
    New P4 trial:  Quantifying Hepatic Mitochondrial Fluxes in Humans (clinicaltrials.gov) -  Mar 31, 2022   
    P4,  N=60, Recruiting, 
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Vitamin D Combined with Pioglitazone Mitigates Type-2 Diabetes-induced Hepatic Injury Through Targeting Inflammation, Apoptosis, and Oxidative Stress. (Pubmed Central) -  Mar 25, 2022   
    Coadministration of VIT D with PIO promoted additional improvement in glycemic and lipid profiles, provided further control on diabetic-induced hepatic inflammation evident by downregulating TLR2, TLR4, and IKK-β while upregulating IκB-α expression and reducing inflammatory cytokines namely; NF-κB, TNF-α, IL-6, and IL-1β, decreasing apoptosis and oxidative stress by hampering caspase-3 and MDA contents, respectively, and improved liver histology than PIO alone. These beneficial effects of VIT D may expand its use by diabetics combined with antidiabetic drugs due to its anti-inflammatory, antioxidant, and antiapoptotic properties.
  • ||||||||||  irbesartan / Generic mfg., pioglitazone / Generic mfg.
    Journal:  Crosstalk relationship between adiponectin receptors, PPAR-γ and α-adrenoceptors in renal vasculature of diabetic WKYs. (Pubmed Central) -  Mar 24, 2022   
    Exogenously administered adiponectin with full PPAR-γ agonist substantially attenuated renal hemodynamics and improved excretory functions, signifying their renoprotective action. Additionally, a degree of synergism exists between adiponectin and pioglitazone to a large extent compared to combination therapy with irbesartan (partial PPAR-γ agonist) in attenuating the renal vascular receptiveness to adrenergic agonists.
  • ||||||||||  Tasigna (nilotinib) / Novartis, Inhibikase
    Journal:  Drug Repurposing to Target Neuroinflammation and Sensory Neuron-Dependent Pain. (Pubmed Central) -  Mar 24, 2022   
    For our analysis, we subdivide the drugs into substances that can target neuroinflammation or substances that can act on peripheral sensory neurons, and highlight the proposed mechanisms. Finally, we discuss the merits and challenges of drug repurposing for the development of novel analgesics.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Protective role of activating PPARγ in advanced glycation end products-induced impairment of coronary artery vasodilation via inhibiting p38 phosphorylation and reactive oxygen species production. (Pubmed Central) -  Mar 19, 2022   
    Isometric force measurements showed that activating PPARγ by pioglitazone (10 mg/kg/d, intragastric administration) improved the impairment of coronary artery vasodilation, and western blot analysis showed that activating PPARγ increased the Kv 1.2 and Kv 1.5 protein expression, while inhibiting PPARγ by GW9662 (10 mg/kg/d, intraperitoneal injection) attenuated these effects in ZDF rats...Moreover, activating PPARγ by LV-Pparg inhibited AGEs-induced phosphorylation of p38 MAPK, by which could reduce AGEs-mediated NOX2, p22phox expression and ROS production, while CSMCs treatment with SB203580 (10 μmol/L), a p38 MAPK inhibitor, attenuated these effects. Activating PPARγ plays a protective role in AGEs-induced impairment of coronary artery vasodilation by inhibiting p38 phosphorylation to attenuate NOX2 and p22phox expression and further decrease oxidative stress induced by ROS overproduction.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Preclinical, Journal:  Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention. (Pubmed Central) -  Mar 17, 2022   
    This was functional in both preneoplastic and oral cancer cell lines. A better understanding of the molecular mechanism on downstream effects on cellular proliferation could potentially have implications clinically, both in oral preneoplasia and possibly head and neck cancer; however, more research needs to be done to explore the potential these medications have in chemoprevention.
  • ||||||||||  Ocaliva (obeticholic acid) / Intercept, aldafermin (NGM282) / NGM Biopharma, lanifibranor (IVA337) / Inventiva
    Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials (Poster Area) -  Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1689;    
    A better understanding of the molecular mechanism on downstream effects on cellular proliferation could potentially have implications clinically, both in oral preneoplasia and possibly head and neck cancer; however, more research needs to be done to explore the potential these medications have in chemoprevention. Since semaglutide and pioglitazone appear to be more effective on NASH activity while aldafermin, lanifibranor and obeticholic acid perform better on the evolution of fibrosis, combination therapies should be assessed prospectively in subjects who are less likely to improve spontaneously over time, i.e. older patients with biochemically active disease.
  • ||||||||||  pioglitazone / Generic mfg.
    Journal:  Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. (Pubmed Central) -  Mar 15, 2022   
    This transient increase was detected in substantia nigra, striatum, hippocampus, and dorsolateral prefrontal cortex The short-term impact of pioglitazone on PON2 expression in striatum may contribute to the discrepancy in the potency of the drug between short-term animal models and clinical trials for Parkinson's disease. Both PON2 and pioglitazone's receptor, peroxisome proliferator-activated receptor gamma (PPARγ), possess sex- and brain region-dependent expression, which may play a role in the short-term effect of pioglitazone and provide clues to extending the beneficial effects of PON2 activation.